← Novartis overview

Novartis vs Sanofi SA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novartis AG (NOVN.SW)

Q3 2026
▼4▲3

Novartis Q3: Approvals and Deals Offset Entresto Plunge and Trial Failures

  • EU approval of Itvisma gene therapy Novartis won European approval for Itvisma, a one-time gene therapy for a rare genetic disorder. This adds a new high-value treatment to its portfolio and supports future revenue growth.

    New approval is a concrete positive catalyst for the stock.

  • FDA full approval of Fabhalta The FDA granted full approval to Fabhalta for a rare kidney disease, removing a prior restriction. This expands the patient population and strengthens Novartis's rare-disease franchise.

    Full approval is a new milestone that can boost sales and sentiment.

  • Q2 earnings beat and return to sales growth Novartis reported second-quarter results that beat expectations, with sales returning to growth. This reassured investors that the core business remains healthy despite patent challenges.

    Earnings beat is a key driver of stock performance in the quarter.

  • Entresto sales plunge 50% on generics Sales of heart drug Entresto fell by half as generic competitors entered the market, costing about $4 billion in annual revenue. This is a major headwind to earnings and growth.

    The loss of a top-selling drug's exclusivity is a significant negative force.

  • Late-stage trial failures for pelacarsen and del-desiran Two experimental drugs, pelacarsen for heart disease and del-desiran for a muscle disorder, failed in late-stage trials. These setbacks reduce the pipeline's potential and raise doubts about future growth.

    Trial failures are a direct negative for pipeline value and investor confidence.

  • Eight CAR-T trials paused after patient deaths Novartis paused eight CAR-T cancer trials following patient deaths. This raises safety concerns, delays potential new treatments, and could hurt its oncology reputation.

    Safety issues can derail a promising area and weigh on the stock.

  • Activist investor demands board overhaul amid high debt Top shareholder Artisan Partners pushed for a board shake-up, citing $39.4 billion in net debt. This adds governance uncertainty and pressure on management to improve performance.

    Activist pressure can lead to strategic changes and short-term volatility.

  • Pipeline wins and acquisitions offset setbacks Novartis advanced remibrutinib, expanded Pluvicto's label, and acquired Myricx Bio and Tourmaline Bio in deals worth billions. These moves show continued investment in innovation despite recent failures.

    These positive pipeline and deal activities are new and balance the negative news.

August 2026
▲3▼1

Pipeline wins and deals offset CAR-T safety setback

  • Remibrutinib MS and hives approvals Remibrutinib won two Phase 3 MS trials and gained FDA approval (Rhapsido) for chronic hives, adding a new revenue stream and strengthening the company's immunology franchise.

    This is a major pipeline win that supports future growth and was not in earlier reports.

  • Pluvicto expanded to earlier prostate cancer Pluvicto was approved for earlier prostate cancer, nearly doubling the number of eligible patients. This expands the market for an existing drug and could significantly boost sales.

    This approval opens a larger patient population and is a new positive catalyst for the stock.

  • Tourmaline Bio acquisition and licensing deals Novartis acquired Tourmaline Bio for $1.4 billion, adding a Phase III cardiovascular drug, and signed licensing deals with Alteogen (up to $3.2 billion) and Abogen (up to $7.8 billion).

    These deals bolster the pipeline and show strategic investment in future growth, a new development this period.

  • CAR-T trial pause and pelacarsen failure Eight CAR-T trials were paused after three patient deaths, raising safety and regulatory risk. Pelacarsen failed its main Phase 3 heart trial goal, removing a growth driver. Shares already trade above many value estimates.

    These setbacks are new negative developments that could pressure the stock and offset positive news.

Latest
▲4

Novartis wins new drug approvals and deals, but pipeline setbacks linger

  • FDA approves Pluvicto for earlier prostate cancer The FDA approved Pluvicto for metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population. This expands sales of an already marketed drug and strengthens Novartis's position in radioligand therapy, supporting future revenue growth.

    This is a new regulatory approval that directly expands the market for a key Novartis product.

  • FDA approves Rhapsido for chronic hives The FDA approved Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism, a form of chronic hives. This adds a new approved indication for an oral drug that is also being tested in multiple sclerosis, broadening its potential sales.

    A new FDA approval that opens an additional market for a pipeline drug.

  • Novartis buys Tourmaline Bio for $1.4 billion Novartis agreed to acquire Tourmaline Bio for about $1.4 billion, adding pacibekitug, a Phase III-ready anti-inflammatory drug for heart and kidney diseases. This strengthens its cardiovascular pipeline and shows it is still investing in new science despite recent trial failures.

    A major acquisition that adds a late-stage asset and signals continued pipeline investment.

  • New licensing deal with Abogen worth up to $7.8 billion Novartis signed a licensing and option agreement with China's Abogen Biosciences for its lead mRNA cancer asset, ABO2203, worth up to $7.8 billion including $575 million upfront. This adds a new cancer candidate and shows Novartis can attract outside innovation.

    A large new deal that brings in a new pipeline asset and demonstrates deal-making ability.

September 2026
▼2▲1

Pipeline failures and governance pressure hit Novartis in September

  • Late-stage trial failures Pelacarsen and del-desiran failed late-stage trials, erasing billions in potential revenue and market value, while ALS drug rifonebart was halted. These setbacks hurt sentiment and raised doubts about the pipeline.

    Major negative news that directly impacted investor confidence and valuation.

  • Governance pressure from top shareholder Top shareholder Artisan Partners demanded a board overhaul over dealmaking, with net debt at $39.4 billion and eight shareholders raising concerns. This adds uncertainty about strategy and capital allocation.

    Governance issues can weigh on stock price and investor trust.

  • Pipeline wins and licensing deals Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing for polymyalgia rheumatica, and Novartis signed licensing deals worth up to $8.1 billion plus acquired Sironax's brain-delivery platform, signaling continued investment in innovation.

    Positive pipeline news and deals support future growth despite recent failures.

▲2▼2

Novartis adds two big pipeline deals; board pressure and CAR-T pause persist

  • Novartis licenses two new pipeline assets in deals worth up to $8.1 billion Novartis signed a radioligand therapy license with BoomRay (up to $900 million) and an mRNA T-cell engager deal with Abogen (up to $7.2 billion). These add new cancer and autoimmune candidates, showing Novartis can still attract outside innovation and giving investors fresh growth hopes after recent trial failures.

    These are the period's only new positive events and directly counter the pipeline-failure narrative that has weighed on the stock.

  • Artisan Partners publicly demands board shake-up over deal oversight Top-20 shareholder Artisan Partners called for a board overhaul after trial failures wiped out $30 billion in market value. Eight shareholders have raised concerns about Novartis' acquisition strategy. This governance pressure keeps uncertainty high and can weigh on the shares until management responds.

    It is a new escalation of shareholder activism that directly questions Novartis' dealmaking and board, a key overhang on the stock.

  • CAR-T trial pause after three patient deaths continues to raise safety concerns Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological diseases after three deaths from a severe immune reaction. The disclosure came only after an analyst noticed the halted trials. This adds regulatory and safety risk, delaying a promising new treatment area and weighing on sentiment.

    It is a new negative safety event that adds to Novartis' pipeline setbacks and can pressure the share price until reviews clear.

  • EU panel backs Cosentyx for polymyalgia rheumatica, expanding a key drug A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, adding sales for an already marketed drug and offering a modest lift.

    It is a new regulatory win that expands an existing blockbuster into a new indication, supporting near-term revenue growth.

▲2▼2

Novartis hit by three trial failures; pipeline doubts deepen

  • ALS drug rifonebart halted after mid-stage failure Novartis stopped developing its ALS drug rifonebart after it failed its main and secondary goals in a mid-stage trial of 251 patients. This adds to a string of pipeline setbacks, making investors doubt Novartis's ability to turn research spending into new products and pressuring the shares.

    New pipeline failure that directly adds to negative sentiment and future growth doubts.

  • Novartis buys Sironax brain-delivery platform for $125 million Novartis exercised an option to acquire Sironax's brain-delivery technology for $125 million, gaining a way to get large drugs across the blood-brain barrier. This modestly strengthens its neurology pipeline and shows it is still investing in new science despite recent failures.

    New deal that shows continued pipeline investment and a small positive counterweight.

  • EU panel backs Cosentyx for polymyalgia rheumatica A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, expanding sales for an already marketed drug and offering a small lift.

    New regulatory win that broadens an existing product's label and provides a positive offset.

  • Board pressure and $39.4 billion net debt raise capital concerns After the del-desiran failure, top shareholder Artisan Partners demanded a board overhaul, and reports highlighted that Novartis spent over $30 billion on deals, pushing net debt to $39.4 billion. This raises doubts about dealmaking discipline and leaves less room for error, weighing on the stock.

    New details on activist pressure and balance-sheet strain that affect investor confidence.

▼3▲1

Novartis hit by two trial failures, board pressure; MS drug offers hope

  • Pelacarsen heart drug fails, wiping out $6B opportunity Novartis's cholesterol drug pelacarsen failed a final-stage trial, losing a potential $3–6 billion-a-year seller. The news sent shares down 3.3% and removed a key growth driver, making investors question the company's pipeline.

    This is a major pipeline failure that directly hurt the stock and shifts focus to remaining drugs.

  • Muscle-wasting drug del-desiran fails, shares plunge 10–13% The lead asset from Novartis's $12 billion Avidity acquisition failed its pivotal trial, erasing about CHF24–30 billion in market value. This is the third setback in a week and raises doubts about the company's deal-making and pipeline.

    This is the biggest new negative event, causing a record share drop and directly impacting valuation.

  • Top shareholder Artisan Partners demands board shake-up After the record share fall, Artisan Partners publicly urged Novartis to overhaul its board and deal team, citing failed acquisitions. This adds governance and reputational pressure, which can weigh on the stock until management responds.

    This is a new activist investor move that increases uncertainty and could force changes, affecting investor confidence.

  • Remibrutinib beats Sanofi's Aubagio in two late-stage MS trials Novartis's oral MS drug remibrutinib outperformed an older treatment, showing best-in-class potential with no liver-safety issues. Analysts see up to $9 billion in peak sales, offering a bright spot amid recent failures and supporting future growth.

    This is the main positive counterweight, showing pipeline strength and potential to offset losses.

▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

  • CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

    A major safety setback that directly threatens a key pipeline and investor confidence.

  • Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

    The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

  • Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

    A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

  • Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

    A new partnership that supports future product lifecycles and is not already covered.

July 2026
▲4▼2

Novartis pipeline wins and earnings beat offset Entresto decline

  • EU approval for Itvisma gene therapy Novartis received EU approval for its Itvisma gene therapy, adding a new treatment option and reinforcing its position in advanced therapies. This expands the company's portfolio and offers a potential new revenue stream.

    This is a new regulatory win that supports future growth.

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval for Fabhalta in kidney disease, transitioning from accelerated approval. This validates the drug's efficacy and allows broader marketing, potentially boosting sales in a new indication.

    This is a new regulatory milestone that could drive revenue.

  • $1.5B Myricx Bio acquisition Novartis acquired Myricx Bio for $1.5 billion, adding a new asset to its pipeline. This strategic move aims to bolster future growth through external innovation.

    This is a new acquisition that expands the pipeline.

  • Q2 earnings beat with sales returning to growth Novartis reported Q2 earnings that beat expectations, with sales returning to growth despite Entresto's decline. This shows resilience and operational execution, reassuring investors about the company's trajectory.

    This is a new financial result that positively surprised the market.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% as generic competition entered the market, resulting in a $4 billion annual revenue hit. This significant loss pressures overall growth and profitability.

    This is a new negative development impacting financials.

  • UBS turns cautious on Novartis relative to peers UBS downgraded its view on Novartis, citing relative underperformance compared to AstraZeneca and Roche. This cautious stance may limit upside and affect investor sentiment.

    This is a new analyst action that could weigh on the stock.

  • High-stakes late-stage trials could add $10B+ but face failure risk Three late-stage trials (pelacarsen, remibrutinib, del-desiran) could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates meaningful pipeline uncertainty.

    This is a new analyst warning about pipeline risk.

▲2▼1

Novartis wins FDA label expansions, Q2 beat, but Entresto cliff and pipeline risk loom

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval to Fabhalta for slowing kidney decline in IgA nephropathy, upgrading it from accelerated approval. This expands the market for a first-in-class oral drug and adds a new growth driver, supporting the stock.

    This is a new regulatory win that directly boosts Novartis's revenue outlook.

  • Q2 earnings beat and sales return to growth Novartis beat second-quarter profit and sales estimates, with key brands like Kisqali and Pluvicto growing strongly. Sales returned to growth despite Entresto's 50% decline, reassuring investors and lifting the stock.

    The earnings beat is a new event that shows the company's core business is performing better than expected.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% to $1.18 billion as cheaper generics entered the market, a $4 billion annual revenue hit. This drags on overall growth and pressures the stock, though newer drugs are offsetting some of the loss.

    This is a major negative force that explains why Novartis's growth is muted and why the stock faces a headwind.

  • Pipeline bets face high-stakes trial readouts Novartis is relying on three late-stage trials (pelacarsen, remibrutinib, del-desiran) that could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates uncertainty around future growth.

    This highlights the key risk and potential reward that will drive the stock's longer-term direction.

▲3▼1

Novartis advances gene therapy and oncology pipeline, but UBS turns cautious

  • EU approval for Itvisma gene therapy Novartis won European Commission approval for Itvisma, a one-time gene replacement therapy for spinal muscular atrophy in patients aged 2 and older. This expands its approved product portfolio in Europe and opens a new revenue stream, supporting the stock.

    This is a concrete regulatory win that directly adds a new approved product and potential sales.

  • Acquisition of Myricx Bio for up to $1.5B Novartis agreed to buy UK biotech Myricx Bio for up to $1.5 billion, gaining a first-in-class antibody-drug conjugate payload platform and two lead assets. This strengthens its oncology pipeline and shows commitment to high-growth areas, a positive for the stock.

    This is a major strategic deal that bolsters the pipeline and signals growth investment.

  • ianalumab positioned in growing markets Novartis' ianalumab is highlighted as a key late-stage candidate in warm autoimmune hemolytic anemia and systemic lupus erythematosus, both large markets with no approved therapies. Phase III results are expected in 2027, offering a potential future growth driver.

    This points to a significant pipeline opportunity that could drive future revenue.

  • UBS cautious on Novartis UBS reiterated an overweight view on European pharma but was more cautious on Novartis, preferring peers like AstraZeneca and Roche. This relative caution may weigh on sentiment and limit the stock's upside compared to sector peers.

    This is a direct analyst opinion that could influence investor perception and relative performance.

Q2 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

June 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

Sanofi SA (SAN.PA)

Q3 2026
▲2▼2

Pipeline wins offset safety setbacks and rising competition

  • New drug approvals and strong Q2 results Sanofi won FDA approval for subcutaneous Sarclisa Escena and EU approval for MenQuadfi in infants. Q2 sales rose 17.8% with raised guidance, and new drug sales grew 48.3%, supporting the growth story.

    These approvals and financial results are new positive developments that drove investor optimism.

  • Dupixent growth and expanded Regeneron alliance Dupixent continued to grow, and Sanofi expanded its antibody alliance with Regeneron. Nexviazyme also succeeded in phase 3 trials, adding to the pipeline of future growth drivers.

    Dupixent's ongoing growth and new partnership expansion are key positive drivers for future revenue.

  • Safety setbacks halt key programs Sanofi halted amlitelimab for atopic dermatitis and permanently stopped its infant RSV vaccine trial after a death. These safety issues raise concerns about pipeline reliability and future revenue.

    These setbacks are new negative events that weighed on sentiment and future growth prospects.

  • Intensifying competition threatens key products Competition increased from AbbVie, Moderna, Novartis, and AstraZeneca, putting pressure on Sanofi's key products. The Cheplapharm deal simplifies the portfolio but removes steady revenue.

    Rising competition and portfolio simplification are new negative factors affecting Sanofi's market position.

August 2026
▲2▼2

Sanofi's mixed month: pipeline wins, safety setback, rising competition

  • EU approval for MenQuadfi in infants Sanofi won EU approval for MenQuadfi in infants, expanding its meningitis vaccine to a younger age group. This opens a new market and supports future vaccine sales growth.

    New approval expands Sanofi's vaccine franchise and revenue potential.

  • Novavax partnership advances with Phase 3 combo study Sanofi advanced its Novavax partnership by starting a Phase 3 study of a combined COVID/flu vaccine. Success could simplify vaccination and strengthen Sanofi's position in the respiratory vaccine market.

    Shows progress in a key partnership that could yield a differentiated vaccine.

  • Infant RSV vaccine trial halted after death Sanofi permanently halted its infant RSV vaccine trial after an infant death. This removes a potential vaccine from the pipeline and raises safety concerns, weighing on sentiment.

    Major safety setback that eliminates a pipeline asset and damages confidence.

  • Rising competition from AbbVie and Moderna AbbVie is targeting a Dupixent rival, and Moderna launched the first mRNA flu shot. These competitive threats could pressure Sanofi's key products and future growth.

    Competitive landscape intensifies, posing risks to Sanofi's market share.

Latest
▲2▼2

Sanofi's pipeline setbacks and buyback shape mixed outlook

  • Amlitelimab discontinued for atopic dermatitis Sanofi stopped developing amlitelimab for atopic dermatitis after a pipeline review found it was no better than current treatments. This removes a key future immunology drug, which can lower investor expectations for growth and weigh on the stock price.

    This is a major pipeline failure that directly affects Sanofi's future revenue prospects.

  • Advertising watchdog questions Dupixent claims The National Advertising Division recommended Sanofi modify or stop some Dupixent TV and prescriber claims about long-lasting clearer skin and fast itch relief. This could limit marketing and slow sales of Sanofi's biggest drug, a negative for the stock.

    Regulatory scrutiny of Dupixent marketing could hurt sales of Sanofi's top revenue driver.

  • New Phase 1 trial for oral STAT6 degrader Sanofi began a Phase 1 trial of an oral STAT6 degrader for type 2 inflammatory diseases, triggering a $10 million milestone to partner Nurix. This early-stage asset shows pipeline progress and could become a future growth driver, supporting the stock.

    It demonstrates continued pipeline advancement despite the amlitelimab setback.

  • High dividend yield and buyback support valuation Sanofi offers a 5.6% dividend yield and completed a €1 billion buyback, with total shareholder yield near 11%. Dupixent sales grew 31% and the stock trades at a low forward P/E of 9, making it attractive to income and value investors.

    These capital returns and cheap valuation provide a floor for the stock price.

September 2026
▲2▼1

Sanofi's pipeline and partnership news reshape growth outlook

  • New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

    This is a key positive fundamental driver showing Sanofi's growth diversification.

  • Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

    This major partnership expansion is a new positive catalyst for Sanofi's future growth.

  • Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

    These competitive losses directly threaten Sanofi's existing product revenue.

  • Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

    This strategic divestment has ambiguous implications for Sanofi's future earnings.

▲2▼1

Sanofi's pipeline and partnership news reshape growth outlook

  • New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

    This is a key positive fundamental driver showing Sanofi's growth diversification.

  • Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

    This major partnership expansion is a new positive catalyst for Sanofi's future growth.

  • Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

    These competitive losses directly threaten Sanofi's existing product revenue.

  • Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

    This strategic divestment has ambiguous implications for Sanofi's future earnings.

▲2▼2

Sanofi expands infant vaccine reach but faces pipeline and competition setbacks

  • EU approval of MenQuadfi for infants Sanofi won EU approval to use its MenQuadfi vaccine in infants as young as six weeks, opening a new market. This should boost vaccine sales and strengthen Sanofi's pediatric portfolio, supporting the stock price.

    This is a new regulatory win that directly expands Sanofi's vaccine market and revenue potential.

  • Novavax partnership advances with milestones Sanofi's partnership with Novavax is progressing, with a Phase 3 COVID/flu combo study planned and milestone payments ahead. Sanofi will lead commercial launches of Nuvaxovid, adding to its vaccine business and future revenue.

    This shows Sanofi's collaboration is moving forward, with potential milestone income and expanded commercial reach.

  • Permanent halt of infant RSV vaccine trial Sanofi permanently stopped its Phase 3 RSV vaccine trial in infants after an infant death, raising safety and regulatory concerns. This removes a potential future product and may hurt Sanofi's reputation in pediatric vaccines, weighing on the stock.

    This is a major pipeline setback with reputational and regulatory implications that could lower investor confidence.

  • Competition heats up from AbbVie and Moderna AbbVie is buying Apogee to get a drug that could rival Sanofi's top-selling Dupixent, while Moderna won FDA approval for the first mRNA flu shot, challenging Sanofi's flu vaccine franchise. Both threaten key Sanofi products.

    These are new competitive threats that could pressure Sanofi's sales in two major areas: immunology and flu vaccines.

July 2026
▲3▼1

Sanofi Q2 Beat and New Approvals Offset Pipeline Setback

  • FDA approves subcutaneous Sarclisa Escena The FDA approved Sarclisa Escena, the first on-body injector cancer treatment, offering patients a more convenient option and expanding Sanofi's oncology portfolio. This approval supports future revenue growth and boosts investor confidence.

    This is a new regulatory approval that directly supports Sanofi's growth outlook.

  • Q2 results beat expectations, guidance raised Sanofi reported Q2 sales up 17.8%, raised full-year guidance, and saw Dupixent sales surge 37.6% to €5.2bn. Partner Regeneron also posted a strong quarter, reinforcing confidence in Sanofi's growth trajectory.

    Strong quarterly results and raised guidance are key positive drivers for the stock.

  • Nexviazyme meets all phase 3 endpoints Nexviazyme met all phase 3 endpoints in infant Pompe disease, potentially expanding its label and addressing a serious unmet need. This positive trial outcome supports future sales growth and strengthens Sanofi's rare disease franchise.

    A successful phase 3 trial is a new positive catalyst for Sanofi's pipeline.

  • Sanofi halts amlitelimab for atopic dermatitis Sanofi halted development of amlitelimab for atopic dermatitis due to insufficient efficacy and safety, removing a much-anticipated growth driver. This setback weighs on sentiment and raises questions about the pipeline's near-term potential.

    This pipeline failure is a significant negative event that impacts future growth prospects.

▲3▼1

Sanofi raises outlook on Dupixent surge, but pipeline setback weighs

  • Q2 earnings beat and raised 2026 guidance Sanofi reported Q2 sales up 17.8% and raised its 2026 outlook, with Dupixent sales jumping 37.6% to €5.2 billion. This strong performance and confident guidance signal accelerating growth, which should lift investor confidence and support a higher share price.

    This is the most significant new event, directly showing Sanofi's financial health and future prospects.

  • Amlitelimab development halted for atopic dermatitis Sanofi discontinued amlitelimab for moderate-to-severe atopic dermatitis, a key pipeline candidate, due to insufficient efficacy and safety data. This removes a potential growth driver and may hurt sentiment, as investors had high hopes for the drug in a large market.

    This is a major pipeline setback that could negatively impact future revenue expectations.

  • Dupixent partner Regeneron beats estimates Regeneron's strong quarterly results, driven by Dupixent sales up 38% to $6 billion, confirm robust demand for Sanofi's top-selling drug. As Sanofi records these sales, the beat reinforces confidence in Dupixent's growth trajectory and Sanofi's earnings power.

    This provides independent validation of Dupixent's blockbuster performance, a key value driver for Sanofi.

  • Aqemia AI collaboration expands with new target Sanofi expanded its AI-driven drug discovery partnership with Aqemia, nominating a new target and potentially paying up to $140 million in milestones. This strengthens Sanofi's early-stage pipeline and shows commitment to innovative technologies, which could yield future blockbuster drugs.

    This highlights Sanofi's investment in cutting-edge R&D, supporting long-term growth prospects.

▲3▼1

Sanofi pipeline wins and FDA nod offset cautious analyst view

  • FDA approves Sarclisa Escena on-body injector The FDA approved subcutaneous Sarclisa Escena for all multiple myeloma uses, the first anticancer treatment given via on-body injector. It cuts treatment time and infusion reactions, which can lift sales and strengthen Sanofi's cancer franchise.

    This is a new regulatory approval that expands a key product's use and could drive future revenue.

  • Nexviazyme hits all goals in infant Pompe disease trial Sanofi's Nexviazyme met all endpoints in a phase 3 study for infants with infantile-onset Pompe disease, supporting a US label extension filing later in 2026. Success in a rare disease with few options adds a new growth driver.

    Positive late-stage trial data for an existing drug opens a new patient population and revenue stream.

  • WAYRILZ positioned in fast-growing AIHA market A market report projects 14.4% annual growth for warm autoimmune hemolytic anemia treatments through 2036, with no approved therapies yet. Sanofi's WAYRILZ is a key late-stage candidate, giving it a large untapped opportunity if approved.

    Highlights a new market opportunity for a Sanofi pipeline drug, supporting long-term growth prospects.

  • UBS cautious on Sanofi within favored pharma sector UBS likes European pharma as a safer bet than AI but is more cautious on Sanofi, preferring AstraZeneca and Roche. This relative caution may steer some investor money away from Sanofi shares, limiting upside versus peers.

    Analyst preference can influence capital flows and relative stock performance.

Q2 2026
▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

June 2026
▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

▲2▼2

Sanofi wins new drug approvals but faces EU antitrust probe

  • Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

    Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

  • Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

    New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

  • EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

    Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

  • AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

    Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.